康泰生物(300601.SZ)：三价流感病毒裂解疫苗上市许可申请获得受理

Group 1 - The core point of the article is that Kangtai Biological (300601.SZ) has received a notice of acceptance from the National Medical Products Administration for its influenza virus split vaccine application [1] - The influenza virus split vaccine is intended for individuals aged 3 years and older, aiming to stimulate the immune system to produce immunity against influenza viruses [1] - Influenza, caused by the influenza virus, is an acute respiratory infectious disease, and vaccination is the most effective and economical measure to prevent influenza and its outbreaks [1]